Novacyt S.A.
("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK – 25 March 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 25 March 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”):

<table>
<thead>
<tr>
<th>Director</th>
<th>Title</th>
<th>Number of Ordinary Shares purchased</th>
<th>Price paid per Ordinary Share</th>
<th>Resultant beneficial holding</th>
<th>% of issued share capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Allmond</td>
<td>Chief Executive Officer</td>
<td>43,500</td>
<td>£2.31</td>
<td>43,500</td>
<td>0.06%</td>
</tr>
</tbody>
</table>

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. Details of the person discharging managerial responsibilities / person closely associated
   a) Name
      David Allmond, Chief Executive Officer

2. Reason for the Notification
   a) Position/status
      See 1(a) - classified as a PDMR of the Company
   b) Initial notification/ Amendment
      Initial Notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
   a) Name
      Novacyt S.A.
   b) LEI
      213800BWAC2BF295EG28

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
### a) Description of the Financial instrument, type of instrument
ordinary shares of €1/15 each

| Identification code | FR0010397232 |

### b) Nature of the transaction
Acquisition of Ordinary Shares

### c) Price(s) and volume(s)

<table>
<thead>
<tr>
<th>Price</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>£2.31</td>
<td>43,500</td>
</tr>
</tbody>
</table>

### d) Aggregated information:

- Aggregated volume
- Price

<table>
<thead>
<tr>
<th>Price</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>£2.31</td>
<td>43,500</td>
</tr>
</tbody>
</table>

### e) Date of the transaction
25 March 2022

### f) Place of the transaction
AIM

---

### Contacts

**Novacyt SA**
David Allmond, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081

**SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

**Numis Securities Limited (Joint Broker)**
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)